VAXXINITY INC A (VAXX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2023, filed Mar 27, 2024. Each column of the statement tables below links to the filing it was taken from.
This page shows VAXXINITY INC A (VAXX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Vaxxinity's development-stage model converts heavy R&D spending into persistent cash losses while its equity cushion contracts.
In FY2023, net loss of-$56.9M nearly matched operating cash outflow of-$57.2M , indicating that the reported loss largely represented current-period cash consumption rather than mainly non-cash accounting charges. Free cash flow of-$58.0M was only modestly below operating cash flow because capital expenditures were just$803K , so reinvestment was not the main driver of cash usage.
In FY2023, research and development spending was
Total liabilities fell to
Financial Health Signals
VAXXINITY INC A does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
VAXXINITY INC A passes 0 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
VAXXINITY INC A reported a net loss of $56.9M while operations used $57.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
VAXXINITY INC A reported an operating loss of $58.3M against $696K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
VAXXINITY INC A earned -$0.09 per diluted share (EPS) in Q4 2023. This represents an increase of 47.1% from the same quarter a year earlier. Against the prior quarter it is up 10.0%.
Not reported for Q4 2023.
Not reported for Q4 2023.
Not reported for Q4 2023.
Cash & Balance Sheet
VAXXINITY INC A recorded an outflow of $12.3M in free cash flow in Q4 2023, representing a cash shortfall after capex. This represents an increase of 17.0% from the same quarter a year earlier. Against the prior quarter it is up 7.9%.
VAXXINITY INC A held $4.9M in cash as of Q4 2023; long-term debt is not reported for that period.
Not reported for Q4 2023.
Margins & Returns
None of these metrics is reported for Q4 2023.
Capital Allocation
VAXXINITY INC A invested $414K in capex in Q4 2023, funding long-term assets and infrastructure. This represents an increase of 41.8% from the same quarter a year earlier. Against the prior quarter it is up 226.0%.
Not reported for Q4 2023.
Not reported for Q4 2023.
VAXX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $50K | N/A |
| R&D Expenses | N/A | $7.9M-36.6% | $8.3M-21.7% | $11.4M-0.5% | N/A | $12.5M-46.8% | $10.7M-43.9% | $11.5M-1.8% |
| SG&A Expenses | N/A | $5.5M-24.2% | $6.1M-7.3% | $7.4M+10.4% | N/A | $7.3M+6.2% | $6.6M+12.2% | $6.7M-22.1% |
| Operating Income | N/A | -$13.4M+32.0% | -$14.4M+16.2% | -$18.8M-3.5% | N/A | -$19.8M+34.7% | -$17.2M+35.7% | -$18.2M+10.3% |
| EBITDA | N/A | -$12.8M+34.0% | -$13.9M+17.4% | -$18.2M-2.2% | N/A | -$19.3M+35.2% | -$16.8M-106.6% | -$17.8M-106.8% |
| Interest Expense | N/A | $176K+225.9% | $146K+39.0% | $192K+82.9% | N/A | $54K-51.8% | $105K-3.7% | $105K-79.5% |
| Net Income | N/A | -$13.1M+31.7% | -$14.0M+19.0% | -$18.4M-0.9% | N/A | -$19.3M+36.6% | -$17.3M+35.9% | -$18.3M+43.0% |
| EPS (Basic) | -$0.09+47.1% | -$0.10+33.3% | -$0.11+21.4% | -$0.150.0% | -$0.17 | -$0.15 | -$0.14 | -$0.15 |
| EPS (Diluted) | -$0.09+47.1% | -$0.10+33.3% | -$0.11+21.4% | -$0.150.0% | -$0.17 | -$0.15 | -$0.14 | -$0.15 |
| Diluted Shares (Avg) | N/A | 127M+0.6% | 126M+0.4% | 126M+0.3% | N/A | 126M | 126M | 126M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.
VAXX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $44.3M-58.4% | $57.5M-53.3% | $71.4M-47.9% | $85.5M-42.0% | $106.4M-36.2% | $123.0M-8.9% | $137.0M | $147.5M |
| Current Assets | $33.2M-64.6% | $46.4M-57.1% | $59.7M-51.1% | $73.4M-44.9% | $93.9M-39.2% | $108.1M+3.9% | $122.0M | $133.3M |
| Cash & Equivalents | $4.9M-85.3% | $17.4M-7.8% | $37.1M-67.1% | $22.6M-81.9% | $33.5M-76.9% | $18.9M-78.9% | $112.7M+1.6% | $124.8M+153.4% |
| Short-Term Investments | $25.5M-52.3% | $25.1M-68.7% | $18.8M | $45.0M | $53.4M | $80.2M | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $30.9M-30.1% | $33.8M-20.9% | $36.4M-8.3% | $39.4M+13.0% | $44.2M+16.2% | $42.7M-86.0% | $39.7M | $34.9M |
| Current Liabilities | $17.6M-43.1% | $21.6M-33.5% | $23.8M-18.8% | $26.5M+8.4% | $30.9M+12.5% | $32.4M+5.7% | $29.3M | $24.4M |
| Non-Current Liabilities | $13.3M+0.1% | $12.2M+18.9% | $12.6M+21.3% | $12.9M+23.6% | $13.3M+25.8% | $10.3M-96.3% | $10.4M | $10.5M |
| Total Equity | $13.4M-78.4% | $23.7M-70.5% | $35.0M-64.0% | $46.1M-59.0% | $62.2M-51.7% | $80.3M+147.0% | $97.3M+168.5% | $112.7M+197.2% |
| Retained Earnings | -$361.6M-18.7% | -$350.2M-23.2% | -$337.1M-27.2% | -$323.1M-30.4% | -$304.7M-32.8% | -$284.2M-56.8% | -$265.0M | -$247.7M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
VAXX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.8M+18.2% | -$13.2M-15.6% | -$12.2M-15.4% | -$20.1M-2.8% | -$14.5M-3.7% | -$11.4M+45.9% | -$10.5M+40.5% | -$19.5M+30.9% |
| Depreciation & Amortization | $456K-15.6% | $666K+58.9% | $526K+34.2% | $586K+76.0% | $540K+210.3% | $419K+4.8% | $392K-99.9% | $333K-99.9% |
| Stock-Based Compensation | N/A | $1.8M-24.9% | $2.4M+33.2% | $2.2M+2.2% | N/A | $2.4M+61.0% | $1.8M+127.7% | $2.2M-36.7% |
| Capital Expenditures | $414K+41.8% | $127K-60.6% | $90K-83.3% | $172K-75.9% | $292K-77.0% | $322K | $539K | $713K |
| Free Cash Flow | -$12.3M+17.0% | -$13.3M-13.6% | -$12.2M-10.6% | -$20.2M0.0% | -$14.8M+3.0% | -$11.7M | -$11.1M | -$20.2M |
| Investing Cash Flow | -$407K-101.5% | -$6.1M+92.4% | $26.6M+5036.9% | $8.7M+1325.8% | $27.2M+2245.7% | -$80.3M | -$539K | -$713K |
| Financing Cash Flow | -$313K-187.2% | -$379K-385.9% | $126K+2000.0% | -$574K-4200.0% | -$109K-100.2% | -$78K+77.7% | $6K-100.0% | $14K-100.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VAXX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | -34448.0% | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -34504.0% | N/A |
| Return on Equity | N/A | -55.5%-31.5pp | -39.9%-22.2pp | -39.9%-23.7pp | N/A | -24.0% | -17.7% | -16.2% |
| Return on Assets | N/A | -22.9%-7.2pp | -19.6%-7.0pp | -21.5%-9.2pp | N/A | -15.7%+6.9pp | -12.6% | -12.4% |
| Current Ratio | 1.89-1.1x | 2.15-1.2x | 2.51-1.7x | 2.77-2.7x | 3.03-2.6x | 3.33-0.1x | 4.17 | 5.46 |
| Debt-to-Equity | 2.30+1.6x | 1.42+0.9x | 1.04+0.6x | 0.85+0.5x | 0.71+0.4x | 0.53 | 0.41 | 0.31 |
| Asset Turnover | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -22152.0% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| VAXXINITY INC A VAXX | FY2023 | N/A | -$56.9M | N/A | $5.5M | — |
| ORGENESIS INC ORGS | FY2024 | $1.0M | N/A | N/A | $7.9M | — |
| BIOXYTRAN INC BIXT | FY2025 | N/A | -$2.1M | N/A | $2.4M | — |
Where VAXXINITY INC A Ranks
Frequently Asked Questions
Is VAXXINITY INC A profitable?
No, VAXXINITY INC A (VAXX) reported a net income of -$56.9M in fiscal year 2023.
What is VAXXINITY INC A's EBITDA?
VAXXINITY INC A (VAXX) had EBITDA of -$56.1M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
What is VAXXINITY INC A's return on equity (ROE)?
VAXXINITY INC A (VAXX) has a return on equity of -424.6% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.
What is VAXXINITY INC A's free cash flow?
VAXXINITY INC A (VAXX) recorded an outflow of $58.0M in free cash flow during fiscal year 2023. This represents a -0.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is VAXXINITY INC A's operating cash flow?
VAXXINITY INC A (VAXX) recorded an outflow of $57.2M in operating cash flow during fiscal year 2023, representing cash used by core business activities.
What are VAXXINITY INC A's total assets?
VAXXINITY INC A (VAXX) had $44.3M in total assets as of fiscal year 2023, including both current and long-term assets.
What are VAXXINITY INC A's capital expenditures?
VAXXINITY INC A (VAXX) invested $803K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
How much does VAXXINITY INC A spend on research and development?
VAXXINITY INC A (VAXX) invested $35.9M in research and development during fiscal year 2023.
What is VAXXINITY INC A's current ratio?
VAXXINITY INC A (VAXX) had a current ratio of 1.89 as of fiscal year 2023, which is generally considered healthy.
What is VAXXINITY INC A's debt-to-equity ratio?
VAXXINITY INC A (VAXX) had a debt-to-equity ratio of 2.30 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is VAXXINITY INC A's return on assets (ROA)?
VAXXINITY INC A (VAXX) had a return on assets of -128.5% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is VAXXINITY INC A's P/E ratio?
VAXXINITY INC A (VAXX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2023). The market capitalization is $5.5M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is VAXXINITY INC A's price-to-sales ratio?
VAXXINITY INC A (VAXX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $5.5M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does VAXXINITY INC A's liquidity compare with its operating cash outflow?
At the end of fiscal year 2023, VAXXINITY INC A (VAXX) held $30.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $57.2M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is VAXXINITY INC A's Piotroski F-Score?
VAXXINITY INC A (VAXX) has a Piotroski F-Score of 0 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are VAXXINITY INC A's earnings high quality?
VAXXINITY INC A (VAXX) reported a net loss of $56.9M while operations used $57.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can VAXXINITY INC A cover its interest payments?
VAXXINITY INC A (VAXX) reported an operating loss of $58.3M against $696K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.